サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1656920

インフルエンザワクチンの世界市場 - 市場考察、競合情勢、市場予測（2032年）

Influenza Vaccine - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
インフルエンザワクチンの世界市場 - 市場考察、競合情勢、市場予測（2032年）
出版日: 2025年01月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のインフルエンザワクチンの市場規模は、2024年に82億4,744万米ドルであり、2032年までに139億5,082万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで6.87%の成長が見込まれます。インフルエンザワクチン接種へのニーズは主に、咳やくしゃみを介して感染する飛沫によるウイルスの拡散による、世界中でのインフルエンザの流行によって促進されています。インフルエンザワクチンの採用の増加や、ワクチン接種を通じた啓蒙活動を推進する政府の取り組みが、市場成長の主な要因となっています。さらに、世界共通のインフルエンザワクチンを開発するための主要企業による研究開発活動の拡大が、予測期間（2025年～2032年）における市場の成長を促進しています。

インフルエンザワクチンの市場力学

米国疾病予防管理センター（CDC）のデータによると、2022年～2023年の罹患率はパンデミック前のシーズンとほぼ同じであり、約3,100万人がインフルエンザに罹患し、1,400万人の医療従事者が受診し、36万人がインフルエンザ関連で入院しました。2024年4月、Australian Center for Disease Controlによると、2023年、オーストラリアではすでに3万7,700件を超える確定症例が記録され、昨年の同時期と比較して40%の増加となっています。

2023年2月、カナダ政府がインフルエンザワクチン接種の普及状況を調査するために実施したSeasonal Influenza Vaccination Coverage Surveyによると、インフルエンザワクチン接種率は2021年～2022年の39%から2022年～2023年に43%に上昇し、パンデミック前の水準に戻っています。ワクチン接種の場所には顕著な変化が見られ、2019年～2020年シーズンと比較して、薬局（52%）または臨時のワクチンクリニック（12%）でインフルエンザの予防接種を受けることを選択する成人の割合が高くなっています。政府機関は、インフルエンザ予防接種がインフルエンザを予防するもっとも効果的な対策であることを強く示し、予防接種を利用できるよう強く支援しています。

例えば2023年10月、台湾政府はインフルエンザワクチン接種キャンペーンを開始しました。政府は、政府資金による4価インフルエンザワクチン698万回分の接種を継続し、全人口の29.6%に接種範囲を拡大しました。

2023年10月、PfizerとBioNTechは、18歳～64歳の健康な成人を対象に、インフルエンザとCOVID-19の両方を標的としたmRNAベースの混合ワクチン候補の安全性、耐性、免疫反応を評価するフェーズ1/2臨床試験の良好な初期所見を発表しました。

しかし、ワクチン生産に長期間を要することや、季節性株に対する有効性が限定的であることが、市場の成長を制限する主な抑制要因となっています。

インフルエンザワクチン市場のセグメント分析

タイプ別では、不活化インフルエンザワクチンカテゴリが2024年に市場で大きな収益シェアを占めると推定されます。これは、高い安全性と有効性、低い製造コストによるものと考えられ、そのため不活化インフルエンザワクチンは世界中でもっとも高い割合で投与されています。世界保健機関（WHO）が2024年に発表した調査によると、卵や細胞培養液を使って製造された不活化ワクチンは、2022年の季節性インフルエンザワクチンの総量の約98%を占めています。

2023年9月、Clover Biopharmaceuticalsは、中国でのAdimFlu-S（QIS）の上市を発表し、3歳以上の個人への投与が認可された4価の季節性インフルエンザワクチンの上市を開始しました。AdimFlu-S（QIS）は、インフルエンザ予防を目的とした4価の不活化スプリットワクチンです。このワクチンは、2つのA株と2つのB株を含む4つの異なるインフルエンザウイルス株から得られたヘマグルチニンから構成されています。

当レポートでは、世界のインフルエンザワクチン市場について調査分析し、市場規模と予測、過去3年の製品/技術開発、市場の主要企業、利用可能な機会などの情報を提供しています。

目次

第1章 インフルエンザワクチン市場レポートのイントロダクション

第2章 インフルエンザワクチン市場のエグゼクティブサマリー

  • 市場の概要

第3章 競合情勢

第4章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第5章 インフルエンザワクチン市場の主な要因の分析

  • インフルエンザワクチン市場の促進要因
  • インフルエンザワクチン市場の抑制要因と課題
  • インフルエンザワクチン市場の機会

第6章 インフルエンザワクチン市場のポーターのファイブフォース分析

第7章 インフルエンザワクチン市場の評価

  • タイプ別
    • 不活化インフルエンザワクチン
    • 組み換えインフルエンザワクチン
    • 弱毒生インフルエンザワクチン
  • 価数別
    • 三価
    • 四価
  • 製造工程別
    • 卵ベースのワクチン
    • 細胞培養ワクチン
  • 投与経路別
    • 経鼻
    • 全身
  • 流通チャネル別
    • 病院、薬局
    • 政府機関
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 インフルエンザワクチン市場の企業と製品のプロファイル

  • GSK plc
  • Pfizer Inc.
  • BioNTech
  • SINOVAC
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Sanofi
  • AstraZeneca
  • CSL
  • Abbott
  • Novavax
  • Gilead Sciences, Inc.
  • Serum Institute Of India Pvt. Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Novartis AG
  • Cadila Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Zydus Pharmaceuticals, Inc.
  • Panacea Biotec
  • Bharat Biotech

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Influenza Vaccine Market in Global (2022-2032)
  • Table 3: Influenza Vaccine Market in Global by Type (2022-2032)
  • Table 4: Influenza Vaccine Market in Global by Valency (2022-2032)
  • Table 5: Influenza Vaccine Market in Global by Manufacturing Process (2022-2032)
  • Table 6: Influenza Vaccine Market in Global by Route of Administration (2022-2032)
  • Table 7: Influenza Vaccine Market in Global by Distribution Channel (2022-2032)
  • Table 8: Influenza Vaccine Market in Global by Geography (2022-2032)
  • Table 9: Influenza Vaccine Market in North America (2022-2032)
  • Table 10: Influenza Vaccine Market in the US (2022-2032)
  • Table 11: Influenza Vaccine Market in Canada (2022-2032)
  • Table 12: Influenza Vaccine Market in Mexico (2022-2032)
  • Table 13: Influenza Vaccine Market in Europe (2022-2032)
  • Table 14: Influenza Vaccine Market in France (2022-2032)
  • Table 15: Influenza Vaccine Market in Germany (2022-2032)
  • Table 16: Influenza Vaccine Market in the United Kingdom (2022-2032)
  • Table 17: Influenza Vaccine Market in Italy (2022-2032)
  • Table 18: Influenza Vaccine Market in Spain (2022-2032)
  • Table 19: Influenza Vaccine Market in Rest of Europe (2022-2032)
  • Table 20: Influenza Vaccine Market in Asia-Pacific (2022-2032)
  • Table 21: Influenza Vaccine Market in China (2022-2032)
  • Table 22: Influenza Vaccine Market in Japan (2022-2032)
  • Table 23: Influenza Vaccine Market in India (2022-2032)
  • Table 24: Influenza Vaccine Market in Australia (2022-2032)
  • Table 25: Influenza Vaccine Market in South Korea (2022-2032)
  • Table 26: Influenza Vaccine Market in Rest of Asia-Pacific (2022-2032)
  • Table 27: Influenza Vaccine Market in Rest of the World (2022-2032)
  • Table 28: Influenza Vaccine Market in the Middle East (2022-2032)
  • Table 29: Influenza Vaccine Market in Africa (2022-2032)
  • Table 30: Influenza Vaccine Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Influenza Vaccine Market in Global (2022-2032)
  • Figure 3: Influenza Vaccine Market in Global by Type (2022-2032)
  • Figure 4: Influenza Vaccine Market in Global by Valency (2022-2032)
  • Figure 5: Influenza Vaccine Market in Global by Manufacturing Process (2022-2032)
  • Figure 6: Influenza Vaccine Market in Global by Route of Administration (2022-2032)
  • Figure 7: Influenza Vaccine Market in Global by Distribution Channel (2022-2032)
  • Figure 8: Influenza Vaccine Market in Global by Geography (2022-2032)
  • Figure 9: Influenza Vaccine Market in North America (2022-2032)
  • Figure 10: Influenza Vaccine Market in the US (2022-2032)
  • Figure 11: Influenza Vaccine Market in Canada (2022-2032)
  • Figure 12: Influenza Vaccine Market in Mexico (2022-2032)
  • Figure 13: Influenza Vaccine Market in Europe (2022-2032)
  • Figure 14: Influenza Vaccine Market in France (2022-2032)
  • Figure 15: Influenza Vaccine Market in Germany (2022-2032)
  • Figure 16: Influenza Vaccine Market in the United Kingdom (2022-2032)
  • Figure 17: Influenza Vaccine Market in Italy (2022-2032)
  • Figure 18: Influenza Vaccine Market in Spain (2022-2032)
  • Figure 19: Influenza Vaccine Market in Rest of Europe (2022-2032)
  • Figure 20: Influenza Vaccine Market in Asia-Pacific (2022-2032)
  • Figure 21: Influenza Vaccine Market in China (2022-2032)
  • Figure 22: Influenza Vaccine Market in Japan (2022-2032)
  • Figure 23: Influenza Vaccine Market in India (2022-2032)
  • Figure 24: Influenza Vaccine Market in Australia (2022-2032)
  • Figure 25: Influenza Vaccine Market in South Korea (2022-2032)
  • Figure 26: Influenza Vaccine Market in Rest of Asia-Pacific (2022-2032)
  • Figure 27: Influenza Vaccine Market in Rest of the World (2022-2032)
  • Figure 28: Influenza Vaccine Market in the Middle East (2022-2032)
  • Figure 29: Influenza Vaccine Market in Africa (2022-2032)
  • Figure 30: Influenza Vaccine Market in South America (2022-2032)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis
目次
Product Code: DISR0208

Influenza Vaccine Market by Type (Inactivated Influenza Vaccine, Recombinant Influenza Vaccine, and Live Attenuated Influenza Vaccine), Valency (Trivalent, Quadrivalent), Manufacturing Process (Egg-based Vaccine, Cell Culture-based Vaccine), Route of Administration (Nasal, Systemic), Distribution Channel (Hospital and Retail Pharmacy, Government Agencies), Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of influenza and the rising adoption of influenza vaccine

The influenza vaccine market was valued at USD 8,247.44 million in 2024, growing at a CAGR of 6.87% during the forecast period from 2025 to 2032 to reach USD 13,950.82 million by 2032. The need for influenza vaccination is primarily driven by the increasing prevalence of influenza worldwide due to the spread of the virus through droplets transmitted via cough and sneezing. The rising adoption of the influenza vaccine and government initiatives to promote awareness through vaccination are the key factors contributing to the growth of the market. Furthermore, Growing R&D initiatives by key players to develop universal influenza vaccine are driving the influenza vaccine market growth during the forecast period (2025-2032)

Influenza Vaccine Market Dynamics:

According to data provided by the Centers for Disease Control and Prevention (CDC), the morbidity rate during the 2022 to 2023 period mirrored that of pre-pandemic seasons, with approximately 31 million individuals affected by influenza, resulting in 14 million healthcare provider consultations and 360,000 flu-related hospital admissions. In April 2024, according to Australian Center for Disease Control, for the year 2023, Australia had already recorded over 37,700 laboratory-confirmed cases, marking a 40% increase compared to the corresponding period last year.

In February 2023, according to Seasonal Influenza Vaccination Coverage Survey, which is conducted by Government of Canada to collect the adoption of vaccination for influenza, the influenza vaccination coverage saw a rise from 39% during the 2021-2022 period to 43% in 2022-2023, now returning to pre-pandemic levels. A notable shift was observed in the vaccination venues, with a higher proportion of adults opting to receive their flu shot in a pharmacy (52%) or at temporary vaccine clinics (12%) compared to the 2019-2020 season. Government entities strongly providing support to avail vaccination, highlighting that influenza vaccination stands as the most efficacious measure for preventing influenza.

For instance, in October 2023, the Taiwan government launched an influenza vaccination campaign. The government sustained the provision of 6.98 million doses of the quadrivalent government-funded influenza vaccine, extending coverage to 29.6% of the total population.

In October 2023, Pfizer Inc. and BioNTech announced favorable initial findings from a Phase 1/2 clinical trial assessing the safety, tolerance, and immune response of mRNA-based combination vaccine candidates targeting both influenza and COVID-19 in healthy adults aged 18 to 64 years.

However, the long period for vaccine production, and the limited efficacy against seasonal strains, among others are some of the key constraints that may limit the growth of the influenza vaccine market.

Influenza Vaccine Market Segment Analysis:

Influenza Vaccine Market by Type (Inactivated Influenza Vaccine, Recombinant Influenza Vaccine, and Live Attenuated Influenza Vaccine), Valency (Trivalent, Quadrivalent), Manufacturing Process (Egg-based Vaccine, Cell Culture-based Vaccine), Route of Administration (Nasal, Systemic), Distribution Channel (Hospital and Retail Pharmacy, Government Agencies), Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the influenza vaccine market, the inactivated influenza vaccine category is estimated to generate a significant revenue share in the influenza vaccine market in 2024. This can be attributed to the high safety and efficacy and low manufacturing cost, due to this inactivated influenza vaccine has the highest percentage of administration across the globe. According to a study published by the World Health Organization in 2024, inactivated vaccines, manufactured using eggs or cell cultures, accounted for approximately 98% of the total volume of the 2022 seasonal influenza vaccine.

In September 2023, Clover Biopharmaceuticals, announced the launch of AdimFlu-S (QIS) in China, marking the availability of a quadrivalent seasonal influenza vaccine authorized for administration in individuals aged three years and above. AdimFlu-S (QIS) represents a quadrivalent split inactivated vaccine designed for influenza prevention. It comprises hemagglutinin sourced from four distinct influenza virus strains, encompassing two A strains and two B strains.

Inactivated vaccines exhibit greater stability and a lower propensity for mutation compared to live vaccines. This characteristic renders them a preferred option for transportation and storage, as they are less susceptible to temperature fluctuations. This vaccine has a high safety profile and stimulates the immune system to produce antibodies to protect against four strains of the virus.

Therefore, the high efficacy and safety and greater stability associated with the inactivated influenza vaccine category are estimated to contribute to the growth of the segment, thereby driving the growth of the overall influenza vaccine market during the forecast period.

North America is expected to dominate the overall Influenza Vaccine Market:

North America is expected to account for the highest market share of the influenza vaccine market in 2024. This is due to the rising number of influenza cases in the region and growing government support for vaccination programs. These are the factors contributing to the growth of the influenza vaccine market in North America.

According to the data provided by the Centers for Disease Control and Prevention (CDC) in February 2024, between 2010 and 2023, influenza has led to an annual range of 9.3 million to 41 million illnesses and 100,000 to 710,000 hospitalizations. In December 2023, as per the report shared by the Canadian government, in the 2021 to 2022 influenza season, there were 16,126 laboratory-confirmed influenza detections out of a total of 751,900 laboratory tests conducted.

Additionally, government organizations in the region are actively providing support to prevent and treat flu in the region. In 2024, the CDC disclosed the identification of an extra USD 93 million to bolster its ongoing response initiatives for avian influenza. This funding has been allocated for the purposes of influenza prevention and vaccination efforts.

In July 2022, GSK plc announced a partnership agreement with the Government of Canada aimed at providing pandemic and seasonal influenza vaccines to safeguard both Canadian adults and children. Under this contract, GSK provided up to 80 million doses of pandemic influenza vaccine to the Government of Canada in the event of influenza pandemics. Additionally, a total of 16 million doses of seasonal influenza vaccine will be supplied throughout the contract. These are some of the factors contributing to the growth of the influenza vaccine market in the region.

Influenza Vaccine Market Key Players:

Some of the key market players operating in the influenza vaccine market include GSK plc, Pfizer Inc., BioNTech, SINOVAC, Moderna, Inc., Merck & Co., Inc., Sanofi, AstraZeneca, CSL, Abbott, Novavax, Gilead Sciences, Inc., Serum Institute Of India Pvt. Ltd., DAIICHI SANKYO COMPANY, LIMITED, Novartis AG, Cadila Pharmaceuticals, Boehringer Ingelheim International GmbH, Zydus Pharmaceuticals, Inc., Panacea Biotec, Bharat Biotech, and others.

Recent Developmental Activities in the Influenza Vaccine Market:

  • In April 2024, CureVac SE, announced the commencement of Phase 1 for a collaborative venture with GSK marking the initiation of a combined Phase 1/2 investigation into an experimental pre-pandemic vaccine targeting influenza A (H5N1). This is a monovalent vaccine candidate based on mRNA technology and encodes an influenza A H5-antigen.
  • In October 2023, Moderna, Inc. announced the interim findings from the Phase 1/2 trial of mRNA-1083, a potential combination vaccine addressing both influenza and COVID-19, have been reported as favorable. mRNA-1083 showed a strong immunogenicity and safety profile against influenza.

Key Takeaways from the Influenza Vaccine Market Report Study

  • Market size analysis for current Influenza Vaccine Market size (2024), and market forecast for 8 years (2025-2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global Influenza Vaccine market.
  • Various opportunities available for the other competitors in the Influenza Vaccine Market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current Influenza Vaccine market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Influenza Vaccine market growth in the coming future?

Target Audience who can be benefited from this Influenza Vaccine Market Report Study

  • Influenza Vaccine product providers
  • Research organizations and consulting companies
  • Influenza Vaccine related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Influenza Vaccine
  • Various end-users who want to know more about the Influenza Vaccine Market and the latest developments in the Influenza Vaccine Market.

FREQUENTLY ASKED QUESTIONS FOR THE INFLUENZA VACCINE MARKET:

1. What are Influenza Vaccine?

  • An influenza vaccine is a proactive solution aimed at mitigating the impact of influenza viruses. It comprises either inactivated or weakened strains of the virus, or its fragments, stimulating the body's immune response to produce antibodies. These antibodies serve as a defense mechanism against the virus upon subsequent exposure. Given the virus's tendency to mutate, necessitating regular updates, influenza vaccines are typically administered annually to maintain efficacy.

2. What is the market for Influenza Vaccine?

  • The influenza vaccine market was valued at USD 8,247.44 million in 2024, growing at a CAGR of 6.87% during the forecast period from 2025 to 2032 to reach USD 13,950.82 million by 2032.

3. What are the drivers for the global Influenza Vaccine market?

  • The need for influenza vaccination is primarily driven by the increasing prevalence of influenza worldwide due to the spread of the virus through droplets transmitted via cough and sneezing. The rising adoption of the influenza vaccine and government initiatives to promote awareness through vaccination are the key factors contributing to the growth of the market. Furthermore, Growing R&D initiatives by key players to develop universal influenza vaccine are driving the influenza vaccine market growth during the forecast period (2025-2032).

4. Who are the key players operating in the global Influenza Vaccine market?)

  • Some of the key market players operating in the influenza vaccine include GSK plc, Pfizer Inc., BioNTech, SINOVAC, Moderna, Inc., Merck & Co., Inc., Sanofi, AstraZeneca, CSL, Abbott, Novavax, Gilead Sciences, Inc., Serum Institute Of India Pvt. Ltd., DAIICHI SANKYO COMPANY, LIMITED, Novartis AG, Cadila Pharmaceuticals, Boehringer Ingelheim International GmbH, Zydus Pharmaceuticals, Inc., Panacea Biotec, Bharat Biotech, and others.

5. Which region has the highest share in the global Influenza Vaccine market?

  • North America is expected to account for the highest market share of the influenza vaccine market in 2024. This is due to the rising number of influenza cases in the region and growing government support for vaccination programs. These are the factors contributing to the growth of the influenza vaccine market in North America.

Table of Contents

1. Influenza Vaccine Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Influenza Vaccine Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Influenza Vaccine Market Key Factors Analysis

  • 5.1. Influenza Vaccine Market Drivers
    • 5.1.1. Increasing Prevalence of Influenza
    • 5.1.2. The rising adoption of influenza vaccine
    • 5.1.3. Government initiatives to promote awareness through vaccination
    • 5.1.4. Growing R&D initiatives by key players
  • 5.2. Influenza Vaccine Market Restraints and Challenges
    • 5.2.1. Long period for vaccine production
    • 5.2.2. Limited efficacy against seasonal strains
  • 5.3. Influenza Vaccine Market Opportunity
    • 5.3.1. Need to develop faster production technology
    • 5.3.2. Constant drug discovery to develop universal vaccines

6. Influenza Vaccine Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Influenza Vaccine Market Assessment

  • 7.1. By Type
    • 7.1.1. Inactivated Influenza Vaccine
    • 7.1.2. Recombinant Influenza Vaccine
    • 7.1.3. Live Attenuated Influenza Vaccine
  • 7.2. By Valency
    • 7.2.1. Trivalent
    • 7.2.2. Quadrivalent
  • 7.3. By Manufacturing Process
    • 7.3.1. Egg-based Vaccine
    • 7.3.2. Cell Culture-based Vaccine
  • 7.4. By Route of Administration
    • 7.4.1. Nasal
    • 7.4.2. Systemic
  • 7.5. By Distribution Channel
    • 7.5.1. Hospitals and Retail Pharmacy
    • 7.5.2. Government Agencies
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.1.2. Canada Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.1.3. Mexico Influenza Vaccine Market Size in USD million (2022-2032)
    • 7.6.2. Europe
      • 7.6.2.1. France Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.2. Germany Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.3. United Kingdom Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.4. Italy Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.5. Spain Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.2.6. Rest of Europe Influenza Vaccine Market Size in USD million (2022-2032)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.2. Japan Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.3. India Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.4. Australia Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.5. South Korea Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.3.6. Rest of Asia-Pacific Influenza Vaccine Market Size in USD million (2022-2032)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.4.2. Africa Influenza Vaccine Market Size in USD million (2022-2032)
      • 7.6.4.3. South America Influenza Vaccine Market Size In USD Million (2022-2032)

8. Influenza Vaccine Market Company and Product Profiles

  • 8.1. GSK plc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Pfizer Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. BioNTech
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. SINOVAC
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Moderna, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Merck & Co., Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Sanofi
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. AstraZeneca
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. CSL
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Abbott
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Novavax
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Gilead Sciences, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Serum Institute Of India Pvt. Ltd.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. DAIICHI SANKYO COMPANY, LIMITED
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Novartis AG
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Cadila Pharmaceuticals
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Boehringer Ingelheim International GmbH
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Zydus Pharmaceuticals, Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Panacea Biotec
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Bharat Biotech
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us